Effect of Ruboxistaurin on Clinically Significant Macular Edema
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin
will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with
clinically significant macular edema. SMVL is defined as a 15 letter or more decrease from
baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity
that is sustained for the patient's last 6 months of study participation. The SMVL data from
this study will be combined with the SMVL data from Study B7A-MC-MBDL for the purpose of
comparing ruboxistaurin to placebo.